WASHINGTON, D.C., United States — A newly identified COVID-19 variant, known as BA.3.2, is spreading rapidly across the United States, prompting renewed scrutiny from health experts monitoring the evolution of the virus.
The variant, nicknamed “Cicada,” has circulated largely unnoticed since late 2024 but is now gaining traction, with confirmed detections in multiple states and through wastewater surveillance systems.
Medical professionals say there is currently no evidence that BA.3.2 causes more severe illness than recent strains. However, its genetic differences may reduce the effectiveness of existing vaccines.
BA.3.2 is a descendant of the COVID-19 virus’ Omicron variant lineage, which first emerged in 2021 and has since produced numerous subvariants.
Researchers first identified BA.3.2 in Africa in November 2024. By early 2026, it had spread to at least 23 countries, reflecting the continued global mobility of the virus.
In the United States, the first recorded case was detected in a traveller in June 2025. Since then, the variant has been identified in patients and wastewater samples across at least 29 states, an early indicator of wider community transmission.
Public health experts note that wastewater monitoring remains one of the most effective early-warning tools for tracking emerging variants, even as participation in such surveillance systems has declined since the peak of the pandemic.
What makes BA.3.2 different?
Like all viruses, SARS-CoV-2 evolves through continuous mutation. BA.3.2 stands out due to the unusually high number of changes in its spike protein, the part of the virus that enables it to enter human cells and the primary target of vaccines.
Scientists estimate the variant carries between 70 and 75 mutations in this region, significantly more than many currently circulating strains.
These changes may make it harder for the immune system to recognise the virus quickly, particularly in individuals whose immunity is based on earlier variants.
Current vaccines in the United States are designed to target strains from the JN.1 lineage, which have dominated since early 2024. Because BA.3.2 differs substantially, it may partially evade immune detection, potentially reducing vaccine effectiveness against infection, though protection against severe illness is expected to remain strong.
Despite its rapid spread, there is no indication that BA.3.2 leads to more severe disease or higher mortality rates compared to recent variants.
However, its ability to spread more easily could result in an increase in case numbers, particularly among populations with lower immunity or underlying health conditions.
Health experts continue to highlight the risk of long COVID, which still affects a small but notable proportion of patients, estimated at around 3% of infections.
Public health guidance remains largely unchanged. Experts recommend regular handwashing, staying home when unwell, and avoiding crowded indoor environments where possible.
Vaccination also continues to play a critical role in reducing severe outcomes, even if protection against infection may be less precise with newer variants.
Individuals with underlying conditions are advised to consult healthcare professionals for personalised guidance on risk mitigation.
Also Read: Nipah virus: Deadly, dangerous — but is it the next pandemic?
The emergence of BA.3.2 underscores a familiar but critical phase in the pandemic’s trajectory: the transition from crisis response to long-term virus management.
While the variant does not currently signal increased severity, its genetic divergence highlights a persistent challenge, vaccine mismatch. As the virus evolves faster than vaccine updates can be deployed globally, periodic waves driven by immune-evasive variants are likely to continue.
However, the situation also reflects progress. Unlike earlier phases of the pandemic, health systems are better equipped, population immunity is higher, and surveillance tools, such as wastewater monitoring, offer early detection capabilities.
The key risk is not necessarily the virulence of BA.3.2, but its transmissibility and the potential strain on healthcare systems if case numbers rise sharply.
Ultimately, BA.3.2 serves as a reminder that COVID-19 remains an endemic global health concern. The focus has shifted from emergency containment to sustained vigilance, where vaccination, public health awareness, and adaptive policy responses remain central to managing future waves.
